Recombinant Adeno-Associated Virus-Mediated Expression of Methamphetamine Antibody Attenuates Methamphetamine-Induced Hyperactivity in Mice

Overview

Journal Sci Rep

Specialty Science

Date 2017 Apr 8

PMID 28387350

Citations 7

Authors

Yun-Hsiang Chen

Kuo-Jen Wu

Kuang-Lun Wu

Kun-Lieh Wu

Ho-Min Tsai

Mao-Liang Chen

Yi-Wei Chen

Wei Hsieh

Chun-Ming Lin

Yun Wang

Affiliations

Soon will be listed here.

Abstract

Methamphetamine (Meth) is one of the most frequently abused drugs worldwide. Recent studies have indicated that antibodies with high affinity for Meth reduce its pharmacological effects. The purpose of this study was to develop a technique for virus-based passive immunization against Meth effects. We generated a recombinant adeno-associated virus serotype-8 vector (AAV-MethAb) carrying the gene for a Meth-specific monoclonal antibody (MethAb). Infection of 293 cells with AAV-MethAb resulted in the expression and secretion of antibodies which bind to Meth. The viral vector was then examined in adult ICR mice. Systemic administration of AAV-MethAb resulted in long-term expression of MethAb in the serum for up to 29 weeks. Serum collected from the animals receiving AAV-MethAb retained a high specificity for (+)-Meth. Animals were challenged with Meth five weeks after viral injection. Meth levels in the brain and serum were reduced while Meth-induced locomotor activity was significantly attenuated. In conclusion, AAV-MethAb administration effectively depletes Meth from brain and serum while reducing the behavioral response to Meth, and thus is a potential therapeutic approach for Meth abuse.

Citing Articles

Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein.

Chiu Y, Wu K, Yu S, Wu K, Wang Y, Lin J PLoS One. 2023; 18(9):e0291927.

PMID: 37733672 PMC: 10513202. DOI: 10.1371/journal.pone.0291927.

Administration of AAV-Alpha Synuclein NAC Antibody Improves Locomotor Behavior in Rats Overexpressing Alpha Synuclein.

Chen Y, Wu K, Hsieh W, Harvey B, Hoffer B, Wang Y Genes (Basel). 2021; 12(6).

PMID: 34205689 PMC: 8233769. DOI: 10.3390/genes12060948.

The potential of adoptive transfer of γ9δ2 T cells to enhance blinatumomab's antitumor activity against B-cell malignancy.

Chen Y, Wang Y, Liao C, Hsu S Sci Rep. 2021; 11(1):12398.

PMID: 34117317 PMC: 8195997. DOI: 10.1038/s41598-021-91784-1.

Association between α1-antitrypsin and acute coronary syndrome.

Liu Y, Huang D, Li B, Liu W, Sooranna S, Pan X Exp Ther Med. 2020; 20(5):119.

PMID: 33005245 PMC: 7523274. DOI: 10.3892/etm.2020.9247.

Gene delivery of a modified antibody to Aβ reduces progression of murine Alzheimer's disease.

Elmer B, Swanson K, Bangari D, Piepenhagen P, Roberts E, Taksir T PLoS One. 2019; 14(12):e0226245.

PMID: 31887144 PMC: 6936806. DOI: 10.1371/journal.pone.0226245.

References

Mitchell A, Nicolson S, Warischalk J, Samulski R . AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther. 2010; 10(5):319-340. PMC: 3920455. DOI: 10.2174/156652310793180706. View

Molitor F, Truax S, Ruiz J, Sun R . Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med. 1998; 168(2):93-7. PMC: 1304836. View

Liu Q, Bowen G, Wong N, Bartlett J, Muruve D . Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol. 2002; 76(9):4580-90. PMC: 155101. DOI: 10.1128/jvi.76.9.4580-4590.2002. View

Kosten T, Owens S . Immunotherapy for the treatment of drug abuse. Pharmacol Ther. 2005; 108(1):76-85. DOI: 10.1016/j.pharmthera.2005.06.009. View

Vocci F, Appel N . Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction. 2007; 102 Suppl 1:96-106. DOI: 10.1111/j.1360-0443.2007.01772.x. View

Ryan M, King A, Thomas G . Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol. 1991; 72 ( Pt 11):2727-32. DOI: 10.1099/0022-1317-72-11-2727. View

Carter B . Adeno-associated virus vectors in clinical trials. Hum Gene Ther. 2005; 16(5):541-50. DOI: 10.1089/hum.2005.16.541. View

Owens S, Atchley W, Hambuchen M, Peterson E, Gentry W . Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord Drug Targets. 2012; 10(8):892-8. PMC: 3653579. DOI: 10.2174/187152711799219370. View

Gentry W, Laurenzana E, Williams D, West J, Berg R, Terlea T . Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol. 2006; 6(6):968-77. DOI: 10.1016/j.intimp.2006.01.008. View

10.

Byrnes-Blake K, Carroll F, Abraham P, Owens S . Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int Immunopharmacol. 2001; 1(2):329-38. DOI: 10.1016/s1567-5769(00)00019-9. View

11.

McMillan D, Hardwick W, Li M, Gunnell M, Carroll F, Abraham P . Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J Pharmacol Exp Ther. 2004; 309(3):1248-55. DOI: 10.1124/jpet.103.061762. View

12.

Laurenzana E, Hendrickson H, Carpenter D, Peterson E, Gentry W, West M . Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. Vaccine. 2009; 27(50):7011-20. PMC: 2792920. DOI: 10.1016/j.vaccine.2009.09.072. View

13.

Shimada M, Abe S, Takahashi T, Shiozaki K, Okuda M, Mizukami H . Prophylaxis and treatment of Alzheimer's disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein. PLoS One. 2013; 8(3):e57606. PMC: 3610755. DOI: 10.1371/journal.pone.0057606. View

14.

Maurer P, Jennings G, Willers J, Rohner F, Lindman Y, Roubicek K . A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005; 35(7):2031-40. DOI: 10.1002/eji.200526285. View

15.

Barr A, Panenka W, MacEwan G, Thornton A, Lang D, Honer W . The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci. 2006; 31(5):301-13. PMC: 1557685. View

16.

Laurenzana E, Byrnes-Blake K, Milesi-Halle A, Gentry W, Williams D, Owens S . Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab Dispos. 2003; 31(11):1320-6. DOI: 10.1124/dmd.31.11.1320. View

17.

Fang J, Qian J, Yi S, Harding T, Tu G, VanRoey M . Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol. 2005; 23(5):584-90. DOI: 10.1038/nbt1087. View

18.

Sullivan Jr J . Immunotherapy in the poisoned patient. Overview of present applications and future trends. Med Toxicol. 1986; 1(1):47-60. DOI: 10.1007/BF03259827. View

19.

Gao G, Alvira M, Wang L, Calcedo R, Johnston J, Wilson J . Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002; 99(18):11854-9. PMC: 129358. DOI: 10.1073/pnas.182412299. View

20.

Rohr U, Wulf M, Stahn S, Steidl U, Haas R, Kronenwett R . Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J Virol Methods. 2002; 106(1):81-8. DOI: 10.1016/s0166-0934(02)00138-6. View